Search Results for: 124

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11, […]

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET-

— Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., March 4,

— SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 — — Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

— Company Provides Update on Late-stage Microbiome-focused Product Candidates — — Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) — ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a

— First Allowed Patent Application Directly Related to SYN-004 in the U.S. — ROCKVILLE, Md., Oct. 22, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel pathogen-specific therapies for serious infections and diseases, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition

ROCKVILLE, Md., Sept. 7, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company’s novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has

— Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 — ROCKVILLE, Md., Sept. 2, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its

— Study to Define Impact of Beta-Lactam Antibiotics on Intestinal Bacteria — ROCKVILLE, Md. and PARIS, June 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative